Form 4: Korro Bio SVP Finance Receives RSU Grant

Korro Bio, Inc. (KRRO) Senior Vice President of Finance, Oliver Dolan, was granted 21,482 restricted stock units (RSUs) under the company's 2023 Stock Option and Incentive Plan.

Summary

• Oliver Dolan, Senior Vice President, Finance at Korro Bio, Inc. (KRRO), received a grant of 21,482 shares of common stock.
• The transaction date for this acquisition was December 15, 2025.
• These shares represent restricted stock units (RSUs) granted under the Issuer's 2023 Stock Option and Incentive Plan.
• The RSUs will vest in two equal tranches: 50% on June 15, 2026, and the remaining 50% on December 15, 2026.
• Vesting is contingent upon Mr. Dolan maintaining a continuous Service Relationship with the company through each such date.
• The acquisition price for these RSUs was $0.00 per share, as is typical for RSU grants.
• Following this transaction, Mr. Dolan beneficially owns 21,482 shares of common stock directly.

Sentiment

Score: 6

Explanation: The RSU grant is a standard executive compensation event, generally viewed as a positive for executive retention and alignment of interests, but not a significant market-moving event on its own.

Positives

• Aligns management's interests with shareholders through equity ownership.
• Serves as a retention mechanism for key executive talent.
• Standard component of executive compensation packages, indicating ongoing commitment to the executive.

Negatives

• Potential for future minor dilution of existing shareholders upon vesting and issuance of shares.

Risks

• Forfeiture of unvested RSUs if the reporting person's service relationship with the company terminates before vesting dates.

Future Outlook

The grant of restricted stock units with future vesting dates indicates an expectation of continued service from the Senior Vice President of Finance and aligns his future financial incentives with the company's long-term performance.

Industry Context

Granting restricted stock units is a common practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives and employees, linking their compensation to the company's stock performance and long-term success.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as a component of executive compensation is a standard practice across the biotech and broader technology sectors, comparable to compensation structures at companies like Moderna, Biogen, or Vertex Pharmaceuticals.
• The vesting schedule, typically over several years and contingent on continued service, is also standard, designed to promote long-term retention and align executive interests with shareholder value creation.

Stakeholder Impact

• Shareholders: Minor potential future dilution upon RSU vesting, but also benefits from enhanced executive retention and alignment of interests.
• Employees: Reinforces the company's commitment to equity-based compensation for key personnel.

Next Steps

• Vesting of 50% of RSUs on June 15, 2026.
• Vesting of the remaining 50% of RSUs on December 15, 2026.

Key Dates

Keywords

Korro Bio, KRRO, Oliver Dolan, Form 4, SEC Filing, Restricted Stock Units, RSU Grant, Executive Compensation, Insider Transaction, Equity Award, 2023 Stock Option and Incentive Plan